Tumor Immunotherapy: Version II
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Cancer Vaccines and Immunotherapy".
Deadline for manuscript submissions: closed (31 July 2022) | Viewed by 2462
Special Issue Editor
2. Laboratory of Innate Immunity, IRCCS MultiMedica, Milan, Italy
Interests: natural killer cells; innate lymphoid cells; tumor microenvironment; tumor angiogenesis; tumor immunology; immunotherapy
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Immunotherapy has emerged as the next-generation frontier in cancer treatments, leading to relevant success in diverse cancer types, such as melanoma and lung cancer. However, in this successful scenario, there is still an “unsuccessful” window for some cancer types. Immunotherapy targets, employs, and re-educates the immune cells of the host, clearly making the tumor immune microenvironment (TIME) the relevant orchestrator for therapeutic outcomes in cancer patients. For the “unsuccessful” window, an increasingly deep investigation into the tumor–immune cell interactions within the tumor microenvironment (TME) still represents an unmet pre-clinical and clinical need to better design successful and patient-oriented (immuno)therapeutic approaches.
Potential topics for this Special Issue include, but are not limited to, the following:
- The tumor (immune)-microenvironment as a target for immunotherapy;
- Immune cell polarization and immunotherapy;
- Immune cell angiogenic switch and immunotherapy;
- Molecular pathways in immunotherapy;
- Strategies to re-educate immune cells in cancers;
- Combination therapies acting on the immune system in cancer;
- Delivering strategies in immunotherapy;
- Nanotechnologies in immunotherapy;
- Phytochemicals endowed with immunostimulatory actions for immunotherapy approaches, including vaccines;
- Marine drugs endowed with immunostimulatory actions for immunotherapy approaches, including vaccines.
Dr. Antonino Bruno
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- innate immunity
- adaptive immunity
- immune cell polarization
- immune cell re-education
- immunotherapy
- combinations in/with immunotherapy
